Skip to content
Our šŸŽÆ Q1 2026 Psychedelic Pipeline Bullseye Charts are now available.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
Menu
  • Pα+
Search
Join Pα+
  • Sign in
Menu
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Join Pα+
Search
Close this search box.
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+
  • Sign in
Read more about the article Psychedelic Research Bulletin: January 2022

Psychedelic Research Bulletin: January 2022

  • Post published:February 7, 2022
  • Post category:Psychedelics Research Review
Read more about the article Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

Psychedelic Bulletin: Patent Granted Covering DMT Vapes; Microdosing Produces “Negligible” Effects

  • Post published:February 6, 2022
  • Post category:Psychedelic Bulletin
Read more about the article Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

Silo Pharma Extends Exclusive Option Agreement for Homing Peptides

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article Entheon Biomedical Announces the Approval of DMT Clinical Trial

Entheon Biomedical Announces the Approval of DMT Clinical Trial

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

MINDCURE Hires Dr. Clare Purvis from Headspace to the position of Chief Product Officer to Advance Mental Health Digital Therapeutics Platform

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity Study of AME-1

Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity Study of AME-1

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its ā€œMicrodosingā€ Compounds

Mindset Pharma Aims to Treat Broader Addressable Neurology Market by Studying Cognitive Benefits of its ā€œMicrodosingā€ Compounds

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

  • Post published:February 3, 2022
  • Post category:Press Release
Read more about the article Looking Ahead to a Psychedelic 2022

Looking Ahead to a Psychedelic 2022

  • Post published:February 3, 2022
  • Post category:Analysis
Read more about the article IntelGenx Receives Third Loan Tranche from atai

IntelGenx Receives Third Loan Tranche from atai

  • Post published:February 1, 2022
  • Post category:Press Release

End of content

No more pages to load

← Newer Posts
Older Posts →

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond. Psy Alpha Ltd is a company registered in England and Wales (16989109).

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha Ā© 2026, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More